Canexia Health


Canexia Health




Reimbursement, Business Development, Regulatory Strategy, Stakeholder mapping, Regulatory Submission Development, Engagement with Stakeholders, Regulatory Document Creation, Regulatory Leadership, Gap Analysis, Market Analysis


Diagnostics, Canadian Digital Super Cluster, Devices


To map out the reimbursement landscape of the canadian regulatory system to provide insight to the company

"With its broad bandwidth of resources, Novateur was an excellent choice to conduct our reimbursement study and we are looking forward to continuing working with them in the future.”

Michael Ball, CEO, Canexia Health


As part of a Canadian Supercluster project, Canexia Health teams up with Novateur to investigate reimbursement strategy for cancer ‘liquid biopsy’

Canexia Health engaged Novateur’s expert team in 2020 to run a pan-Canadian reimbursement study as part of Project ACTT -- Access to Cancer Testing & Treatment in Response to COVID-19.

With a strategic investment from Canada’s Digital Technology Supercluster, Project ACTT is speeding up cancer testing for targeted treatment selection during and beyond the pandemic through a minimally invasive ‘liquid biopsy’ test that analyzes circulating tumor DNA (ctDNA).

ctDNA testing, which requires only a simple blood draw from the patient, can be an effective alternative to some surgical tissue biopsies to guide cancer targeted treatment and can improve patient outcomes two- to three-fold. Yet, this testing is not accessible to most Canadian cancer patients. 

Ultimately, Canexia is working with Novateur to demonstrate that ctDNA testing should be delivered under provincial health coverage -- making it accessible to Canadian cancer patients regardless of where they live. 

Learn more about Canexia Health

Novateur Newsletter

Subscribe to our newsletter for access to latest updates.

Resource Databases

Access Novateur news as well as FDA and Expert Databases.

Relevant Events

Check out conferences and events we are attending!